Mediastinal malignant lymphoma

Summary

Mediastinal malignant lymphoma (MONDO:0004021) is a cancer and 11 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, tazemetostat, and cytarabine. A subtype of lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mediastinal malignant lymphoma
Mondo ID	MONDO:0004021
DOID	DOID:6868
NCIT	C6633
UMLS	C1334665
MedGen	235311
GARD	0023781
Anatomy (UBERON)	UBERON:0003728
Is cancer (heuristic)	yes

Also known as: lymphoma of mediastinum · lymphoma of the mediastinum · mediastinal lymphoma · mediastinal malignant lymphoma · mediastinum lymphoma · primary mediastinal lymphoma

Disease family

This is a subtype of lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › mediastinal malignant lymphoma

Related subtypes (26): prostate lymphoma, nasal cavity lymphoma, bladder lymphoma, tracheal lymphoma, retroperitoneal lymphoma, ureteral lymphoma, ovarian lymphoma, B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, pediatric lymphoma, adult lymphoma, breast lymphoma, heart lymphoma, chest wall lymphoma, lung lymphoma, eye lymphoma, B-cell neoplasm, gastrointestinal lymphoma, Hodgkins lymphoma, peripheral T-cell lymphoma, not otherwise specified, composite lymphoma, AIDS-related primary central nervous system lymphoma, primary organ-specific lymphoma, non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, methotrexate-associated lymphoproliferative disorders, progressive transformation of germinal centers

Subtypes (2): thymus lymphoma, mediastinal gray zone lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	5
Not specified	3
PHASE4	1
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05518383	PHASE4	RECRUITING	B-cell Mature Non-Hodgkin’s Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT06188676	PHASE3	RECRUITING	Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
NCT04787263	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
NCT02568553	PHASE1	COMPLETED	Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02950220	PHASE1	COMPLETED	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03010982	PHASE1	COMPLETED	Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
NCT03019666	PHASE1	COMPLETED	Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
NCT03028103	PHASE1	COMPLETED	Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
NCT03969693	Not specified	NOT_YET_RECRUITING	Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation
NCT04613388	Not specified	RECRUITING	Registry Study of Proton Radiotherapy in Lymphoma
NCT02769299	Not specified	COMPLETED	Cardiotoxicity of Radiation Therapy (CTRT)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	3
TAZEMETOSTAT	4	2
CYTARABINE	4	1
DOXORUBICIN HYDROCHLORIDE	4	1
ETOPOSIDE	4	1
ETOPOSIDE PHOSPHATE	4	1
IFOSFAMIDE	4	1
PEGFILGRASTIM	4	1
REPAGLINIDE	4	1
VINCRISTINE	4	1
CHEMBL5398431	0	2